Stocks online

NameBest
buy
Best
sell
Change
(%)
CETV--0.00sentiment_arrow
ČEZ--0.00sentiment_arrow
E4U--0.00sentiment_arrow
ERSTE--0.00sentiment_arrow
Fortuna--0.00sentiment_arrow
KB--0.00sentiment_arrow
Kofola--0.00sentiment_arrow
MONETA--0.00sentiment_arrow
O2 C.R.--0.00sentiment_arrow
Pegas--0.00sentiment_arrow
PM--0.00sentiment_arrow
STOCK--0.00sentiment_arrow
TMR--0.00sentiment_arrow
UNI--0.00sentiment_arrow
VIG--0.00sentiment_arrow
24/11/2017 08:00:44

Indices online

FOREX ONLINE

Currency
pair
 Best
buy
Best
sell
Change
(%)
EUR/CZK25.397125.46280.01sentiment_arrow
EUR/HUF312.2132312.7662-0.01sentiment_arrow
EUR/PLN4.20764.2092-0.01sentiment_arrow
EUR/RON4.64584.65880.00sentiment_arrow
USD/CZK21.439421.48940.03sentiment_arrow
USD/HUF263.5600263.96000.01sentiment_arrow
USD/PLN3.55193.55240.01sentiment_arrow
USD/RON3.92183.9318-0.01sentiment_arrow
24/11/2017 07:59:46
Delayed data, Real-time data info

Detail - articles
DEVGEN: Monsanto bullish on RNAi, moves lead to phase 3

DEVGEN: Monsanto bullish on RNAi, moves lead to phase 3

06/01/2012 12:32

During its annual R&D update, Monsanto announced that it is moving its corn rootworm III project into phase III. This project contains Devgen’s RNAi technology.

Our View:

During the presentation and conference call, Monsanto was very bullish on the obtained results and future opportunities this technology, citing several arguments:
1. It is the first agricultural application of RNAi. It targets rootworms with a novel mode of action that is outside of the class of BT proteins that have been used in all other insect control products. In fact, RNAi offers a mode of action different from the BT mode of action in the other Monsanto products.
2. Leverages Monsanto's genomic investments because it is based on the identification of key DNA sequences in insects and allows to tap into the naturally occurring machinery in the bugs to design new ways to target and control specific insects.
3. Monsanto is the first to move the application of this RNAi technology for insect control into advanced development and in addition to this first trait they also have the next round of RNAi actives in the pipeline demonstrating insect control. Just as importantly, Monsanto is continuing to look at broader product applications for RNAi and is building a broader intellectual property portfolio and further R&D capability to explore it.
4. Monsanto says that its regulatory experience and the advanced product development capabilities should allow them to move this product aggressively through the remaining development cycle. Compared to its current portfolio, the performance of development so far is unprecedented.
5. In terms of efficacy, data was shown suggesting that there is an even better control than Monsanto's dual mode of action SmartStax products. Given the headlines that there's been on rootworm control over the last few months, Monsanto sees this pipeline product as a gold standard in rootworm control and durability that will be a real game changer (for background info the issues with the BT technology, we refer to our 6 Dec. ’11 morning note)
Monsanto’s bullishness shows it sees a lot of opportunity in RNAi in terms of expansion to other crops and insects. Newto us was that Monsanto's Vistive soybean product in phase IV (prelaunch) contains also RNAi. It's unclear to us if this is based on Devgen's RNAi technology and if it is used for insect control, but should the soybean product be approved (expected soon),it will for sure be supportive for the corn rootworm III regulatory review. Given that RNAi is a new technology acting on the genetics of organisms, substantial safety data will have to be provided.

Conclusion:
Although the product/technology may be an important value driver for Monsanto, it is not easy to translate that into cash flow/value for Devgen because we do not know the royalty rate for Devgen, nor do we know in which crops (other than corn) Monsanto is developing the technology. However, Monsanto’s commitment to RNAi will strengthen the ties between the companies and on the short term we would not be surprised Devgen announcing an extension of its R&D collaboration. Rating/target reiterated.


Your opinion
You can start the on-line discussion here. So far there has been no opinion added to the discussion. All users must be signed in (Přihlásit). If you do not have an account where you could sign in, please register zde.

CEEATX Austrian Traded Index
23/11/2017Budapest SE Index
23/11/2017Bucharest SE BET Index
23/11/2017CROBEX Index
23/11/2017 16:00DAX Index
23/11/2017Ljubljana Stock Exchange SBI TOP Index
23/11/2017 15:30OMX Copenhagen PI
23/11/2017OMX Tallinn GI
23/11/2017 15:05OMX Vilnius GI
23/11/2017 15:05PX Index
23/11/2017RTS Index
23/11/2017 16:40SAX Index
23/11/2017Warsaw SE WIG-20 Single Market Index
23/11/2017
Real-time indicationValueChange (%)
ASX All Ordinaries Index 6,047.10 -0.34sentiment_arrow
ATX Austrian Traded Index 3,306.19 -0.30sentiment_arrow
Budapest SE Index 39,962.72 -0.42sentiment_arrow
CECE Index 2,261.71 0.84sentiment_arrow
CAC 40 Index 5,379.54 0.50sentiment_arrow
DAX Index 13,008.55 -0.05sentiment_arrow
S&P 500 2,597.08 -0.08sentiment_arrow
PX Index 1,046.03 0.00sentiment_arrow
FTSE Eurotop 100 Index 2,966.95 -0.09sentiment_arrow
Swiss Market Index 9,315.40 0.25sentiment_arrow
NASDAQ 100 Index 6,386.12 0.12sentiment_arrow
NASDAQ Composite Index 6,867.36 0.07sentiment_arrow
RTS Index 1,159.06 0.00sentiment_arrow
Shanghai SE Composite Index 3,352.99 -2.26sentiment_arrow
FTSE MIB Index 22,368.70 0.24sentiment_arrow
Warsaw SE WIG-20 Single Market Index 2,503.93 0.58sentiment_arrow
X-DAX Index PR 13,025.74 0.14sentiment_arrow
Hang Seng Index 29,707.94 -0.99sentiment_arrow
Toronto SE 300 Composite Index 16,074.30 0.00sentiment_arrow
XETRA Tecdax Performance index 2,573.39 0.33sentiment_arrow